Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

3(60.0%)

N/A

1(20.0%)

Phase 3

1(20.0%)

5Total

Phase 2(3)

N/A(1)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT04257383Not ApplicableCompleted

The Sugira Muryango PLAY Collaborative

Role: collaborator

NCT02000830Completed

Follow up Study of Patients Having Participated in Clinical Trial 64,185-204

Role: lead

NCT01887327Phase 2Completed

Stannsoporfin With Light Therapy for Newborn Babies With Jaundice

Role: lead

NCT00850993Phase 2Terminated

A Safety and Efficacy Trial of Stannsoporfin in Neonates With Hyperbilirubinemia

Role: lead

NCT02685137Phase 3Completed

Efficacy and Safety of Stannsoporfin in Neonates

Role: lead

NCT00115544Phase 2Completed

Safety and Pharmacology of Stanate

Role: lead

NCT00076960Unknown

Compassionate Use of Stanate (TM) [Stannsoporfin]

Role: lead

NCT02685189Terminated

Long-Term Clinical Follow-Up of Children Enrolled in Stannsoporfin Clinical Trial Protocol No. 64,185-06-2(W)

Role: lead

NCT02033096Completed

Observational Follow-up of Participants From Clinical Trial 64,185-202 (NCT00850993)

Role: lead

All 9 trials loaded